Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis.
Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis.
复制标题
将液滴和磁镊的微流体平台：应用于HER2在癌症诊断中的表达。
DOI：
10.1038/srep25540
复制
发表时间：
2016-05-09
影响因子：
4.6
通讯作者：
Descroix S
中科院分区：
文献类型：
--
作者：
Ferraro D;Champ J;Teste B;Serra M;Malaquin L;Viovy JL;de Cremoux P;Descroix S
精准医学的发展，以及靶向治疗和相关分子生物标志物的倍增，要求基因分析方法取得重大进展，允许增加多路复用和实施更复杂的决策树，而不会增加成本或失去鲁棒性。我们提出了一个结合微滴微流体和磁镊子的平台，以全自动和可编程的方式在直接从微量滴度板上取样的250nL液滴中进行RNA纯化，反转录和扩增。与目前的机器人平台相比，该平台减少了约100倍的样品消耗，并减少了人为操作和污染风险。该平台的性能首先在细胞系上进行评估，显示出对少于一个细胞的RNA数量的稳健操作，然后在21个乳腺癌样本队列中进行临床验证，以确定其HER2表达状态，并与已建立的常规临床分析进行盲比较。
The development of precision medicine, together with the multiplication of targeted therapies and associated molecular biomarkers, call for major progress in genetic analysis methods, allowing increased multiplexing and the implementation of more complex decision trees, without cost increase or loss of robustness. We present a platform combining droplet microfluidics and magnetic tweezers, performing RNA purification, reverse transcription and amplification in a fully automated and programmable way, in droplets of 250nL directly sampled from a microtiter-plate. This platform decreases sample consumption about 100 fold as compared to current robotized platforms and it reduces human manipulations and contamination risk. The platform’s performance was first evaluated on cell lines, showing robust operation on RNA quantities corresponding to less than one cell, and then clinically validated with a cohort of 21 breast cancer samples, for the determination of their HER2 expression status, in a blind comparison with an established routine clinical analysis.